Emmanuel Nony;Nicolas Bihoreau;Philippe Klein;Christophe De Romeuf;Sylvie Jorieux;Christine Gaucher;Dominique Bourel
发明人:
Dominique Bourel,Sylvie Jorieux,Christophe De Romeuf,Philippe Klein,Christine Gaucher,Nicolas Bihoreau,Emmanuel Nony
申请号：
US12659824
公开号：
US08501171B2
申请日:
2010.03.23
申请国别(地区):
US
年份:
2013
代理人:
摘要：
The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.
